SEARCH

SEARCH BY CITATION

References

  • 1
    Barlow S, Renwick AG, Kleiner J, Bridges JW, Busk L, Dybing E et al. Risk assessment of substances that are both genotoxic and carcinogenic report of an International Conference organized by EFSA and WHO with support of ILSI Europe. Food Chem Toxicol 2006;44:163650.
  • 2
    Boobis AR. Risk assessment of dietary supplements. Novartis Found Symp 2007;282:325.
  • 3
    Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C et al. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 2006;36:78192.
  • 4
    Boobis AR, Cohen SM, Doerrer NG, Galloway SM, Haley PJ, Hard GC et al. A data-based assessment of alternative strategies for identification of potential human cancer hazards. Toxicol Path 2009;37:71432.
  • 5
    Boobis AR, Daston G, Preston J, Olin S. Application of key events analysis to chemical carcinogens and noncarcinogens. Crit Rev Food Sci Nutr 2009;49:118.
  • 6
    Burke AS, Redeker K, Kurten RC, James LP, Hinson JA. Mechanisms of chloroform-induced hepatotoxicity: oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J Toxicol Environ Health A 2007;70:193645.
  • 7
    Cohen SM. Cell proliferation and carcinogenesis. Drug Metab Rev 1998;30:33957.
  • 8
    Committee on Carcinogenicity. Guidance on a Strategy for the Risk Assessment of Chemical Carcinogens. Department of Health, London, 2004. http://www.iacoc.org.uk/publications/documents/guideline04.pdf (last accessed on 5 August 2009).
  • 9
    Constan AA, Benjamin SA, Tessari JD, Baker DC, Yang RS. 1995 STP Young Investigator Award recipient increased rate of apoptosis correlates with hepatocellular proliferation in Fischer-344 rats following long-term exposure to a mixture of groundwater contaminants. Toxicol Pathol 1996;24:31522.
  • 10
    Constan AA, Sprankle CS, Peters JM, Kedderis GL, Everitt JI, Wong BA et al. Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice. Toxicol Appl Pharmacol 1990;160:1206.
  • 11
    Corley RA, Mendrala AL, Smith FA, Staats DA, Gargas ML, Conolly RB et al. Development of a physiologically based pharmacokinetic model for chloroform. Toxicol Appl Pharmacol 1990;103:51227.
  • 12
    Edwards RJ, Singleton AM, Murray BP, Davies DS, Boobis AR. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem Pharmacol 1995;49:3947.
  • 13
    EFSA (European Food Safety Authority). Guidance of the Scientific Committee on Use of the benchmark dose approach in risk assessment. EFSA J 2009;1150:172. http://www.efsa.europa.eu/EFSA/Guidance_of_Panel/sc_op_ej1150_bmd_en,2.pdf?ssbinary=true (last accessed on 5 August 2009)
  • 14
    EPA (US Environmental Protection Agency). Guidelines for carcinogen risk assessment. http://oaspub.epa.gov/eims/eimscomm.getfile?p_download_id=439797 . 2005 (last accessed on 21 July 2009).
  • 15
    Fausto N, Laird AD, Webber EM. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995;9:152736.
  • 16
    Golden RJ, Holm SE, Robinson DE, Julkunen PH, Reese EA. Chloroform mode of action: implications for cancer risk assessment. Regul Toxicol Pharmacol 1997;26:14255.
  • 17
    Hartig S, Fries S, Balcarcel RR. Reduced mitochondrial membrane potential and metabolism correspond to acute chloroform toxicity of in vitro hepatocytes. J Appl Toxicol 2005;25:3107.
  • 18
    Hernández LG, Van Steeg H, Luijten M, Van Benthem J. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Mutat Res 2009;682:94109.
  • 19
    Ilett KF, Reid WD, Sipes IG, Krishna G. Chloroform toxicity in mice: correlation of renaland hepatic necrosis with covalent binding ofmetabolites to tissue macromolecules. Exp Mol Pathol 1973;19:21529.
  • 20
    IPCS (International Programme on Chemical Safety). Harmonization Project Document No. 2: Chemical-specific adjustment factors for interspecies differences and human variability: guidance document for use of data in dose/concentration-response assessment. WHO, Geneva, 2005. http://whqlibdoc.who.int/publications/2005/9241546786_eng.pdf (accessed 6 August 2009)
  • 21
    IPCS (International Programme on Chemical Safety). Harmonization Project Document No. 3: Principles of Characterizing and Applying Human Exposure Models. WHO, Geneva, 2005. http://whqlibdoc.who.int/publications/2005/9241563117_eng.pdf (accessed 5 August 2009)
  • 22
    Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN, McCarver DG. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 2003;307:4027.
  • 23
    Komulainen H. Experimental cancer studies of chlorinated by-products. Toxicology 2004;198:23948.
  • 24
    Khani SC, Porter TD, Fujita VS, Coon MJ. Organization and differential expression of two highly similar genes in the rabbit alcohol-inducible cytochrome P-450 subfamily. J Biol Chem 1988;263:71705.
  • 25
    Kroes R, Renwick AG, Cheeseman M, Kleiner J, Mangelsdorf I, Piersma A et al. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem Toxicol 2004;42:6583.
  • 26
    Larson JL, Wolf DC, Butterworth BE. Induced cytotoxicity and cell proliferation in the hepatocarcinogenicity of chloroform in female B6C3F1 mice: comparison of administration by gavage in corn oil vs ad libitum in drinking water. Fundam Appl Toxicol 1994;22:90102.
  • 27
    Liao KH, Tan YM, Conolly RB, Borghoff SJ, Gargas ML, Andersen ME et al. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. Risk Anal 2007;27:153551.
  • 28
    Lipscomb JC, Barton HA, Tornero-Velez R, Evans MV, Alcasey S, Snawder JE et al. The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J Toxicol Environ Health A 2004;67:53753.
  • 29
    Marino DJ, Starr TB. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results. Regul Toxicol Pharmacol 2007;49:285300.
  • 30
    Meek ME, Renwick A, Ohanian E, Dourson M, Lake B, Naumann BD et al. Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicology 2002;182:11520.
  • 31
    Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD et al. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 2003;33:591653.
  • 32
    Munro IC, Kennepohl E, Kroes R. A procedure for the safety evaluation of flavouring substances. Joint FAO/WHO Expert Committee on Food Additives. Food Chem Toxicol 1999;37:20732.
  • 33
    Pauluhn J, Carson A, Costa DL, Gordon T, Kodavanti U, Last JA et al. Workshop summary: phosgene-induced pulmonary toxicity revisited: appraisal of early and late markers of pulmonary injury from animal models with emphasis on human significance. Inhal Toxicol 2007;19:789810.
  • 34
    Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:741521.
  • 35
    Reitz RH, Mendrala AL, Corley RA, Quast JF, Gargas ML, Andersen ME et al. Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. Toxicol Appl Pharmacol 1990;105:44359.
  • 36
    Sakamoto T, Liu Z, Murase N, Ezure T, Yokomuro S, Poli V et al. Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology 1999;29:40311.
  • 37
    Snawder JE, Lipscomb JC. Interindividual variance of cytochrome P450 forms in human hepatic microsomes: correlation of individual forms with xenobiotic metabolism and implications in risk assessment. Regul Toxicol Pharmacol 2000;32:2009.
  • 38
    Sonich-Mullin C, Fielder R, Wiltse J, Baetcke K, Dempsey J, Fenner-Crisp P et al. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol 2001;34:14652.
  • 39
    Tan YM, Butterworth BE, Gargas ML, Conolly RB. Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. Toxicol Sci 2003;75:192200.
  • 40
    Templin MV, Larson JL, Butterworth BE, Jamison KC, Leininger JR, Méry S et al. A 90-day chloroform inhalation study in F-344 rats: profile of toxicity and relevance to cancer studies. Fundam Appl Toxicol 1996;32:10925.
  • 41
    WHO (World Health Organization). Dietary Exposure Assessment of Chemicals in Food: Report of a Joint FAO/WHO Consultation, Annapolis, Maryland, USA, 2–6 May 2005. WHO, Geneva, 2008. http://whqlibdoc.who.int/publications/2008/9789241597470_eng.pdf (accessed 5 August 2009)
  • 42
    Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 2006;1757:50917.